In the published article, there was an error in Supplementary Tables 1 and 2. Several units and the order in which the baseline variables appear are written incorrectly. The supplementary material has been updated in the original article.
In the published article, there was also several errors in the text. In the Abstract, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.
A correction has been made to Abstract, Results, paragraph 1.This sentence previously stated:
“For both groups, the median recurrence-free survival (hazard ratio 1.46, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”
The corrected sentence appears below:
“For both groups, the median recurrence-free survival (hazard ratio 1.046, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”
In the Results, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.
A correction has been made to Results, Comparison of RFS and OS between tislelizumab with and without TKIs group, paragraph 6. This sentence previously stated:
“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.46, 95%CI 0.58–1.90, Figure 3A).”
The corrected sentence appears below:
“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.046, 95%CI 0.58–1.90, Figure 3A).”
The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
hepatocellular carcinoma, high-risk of recurrence, tislelizumab, recurrence-free survival, adjuvant therapy
Citation
Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection. Front. Immunol. 16:1669840. doi: 10.3389/fimmu.2025.1669840
Received
20 July 2025
Accepted
08 August 2025
Published
27 August 2025
Volume
16 - 2025
Edited and reviewed by
Takahiro Kodama, Osaka University, Japan
Updates
Copyright
© 2025 Peng, Mao, Su, Liu, Ou, Chen, Su, Li, Yang, Zhou, Li and Zhong.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jian-Hong Zhong, zhongjianhong@gxmu.edu.cn
†These authors have contributed equally to this work
‡ORCID: Jian-Hong Zhong, orcid.org/0000-0002-1494-6396
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.